Introduction: Who Should Seek Diagnostics

Extraosseous Ewing’s sarcoma is a rare form of cancer that starts in the soft tissues—such as muscles, tendons, and ligaments—rather than in bones. When this cancer has spread, or metastasized, to other parts of the body, recognizing when to seek medical attention becomes even more important. Unfortunately, the symptoms can be vague and may appear similar to everyday injuries or infections, which often leads to delays in getting the right diagnosis.^[1]

Anyone experiencing persistent bone pain, especially pain that comes and goes and worsens at night, should consider seeking medical evaluation. This type of pain is not typical of simple muscle strains or growing pains. Swelling or a noticeable lump that appears near bones or in soft tissue areas, particularly if it feels warm to the touch, is another sign that should not be ignored.^[3] These lumps may develop over weeks or months, and because they grow slowly at first, people sometimes dismiss them as harmless bumps or bruises.

When extraosseous Ewing’s sarcoma has already spread to distant parts of the body at the time of diagnosis—which happens in about 25% of cases—additional symptoms may appear. These can include unexplained fever that doesn’t go away, unusual tiredness that doesn’t improve with rest, and weight loss without trying.^[16] Young people and adolescents, who are most commonly affected by this disease, should be especially attentive to these warning signs, as should their parents and caregivers.

It’s also important to understand that extraosseous Ewing’s sarcoma affects slightly older patients on average compared to the bone-based form of the disease. The tumor can appear in various locations throughout the body, including the spaces along the spine, the lower limbs, the head and neck area, and the pelvis. Rarer sites include the area behind the abdominal organs, the tissue lining the abdomen, the eye socket, the skin, and the chest wall.^[1]

Classic Diagnostic Methods

Once a person presents with symptoms that raise concern for extraosseous Ewing’s sarcoma, doctors use a series of tests to confirm the diagnosis and understand the extent of the disease. The diagnostic process typically begins with imaging studies, which allow doctors to see inside the body without surgery, followed by tissue examination to study the cells under a microscope.

Imaging Tests

The first step in diagnosing extraosseous Ewing’s sarcoma often involves imaging tests. These tests help doctors locate the tumor, measure its size, and check whether it has spread to other parts of the body. Ultrasound is sometimes used as an initial tool because it is safe, non-invasive, and can show soft tissue masses. However, ultrasound alone is not enough to make a definitive diagnosis.^[1]

Computed tomography, or CT scans, are commonly used to get detailed images of the tumor and surrounding tissues. A CT scan uses X-rays and a computer to create cross-sectional images of the body, which can reveal the size and location of the tumor more clearly than a regular X-ray. This test is especially helpful in detecting whether the cancer has spread to the lungs or other organs.^[1]

Magnetic resonance imaging, or MRI, provides even more detailed images of soft tissues. MRI uses powerful magnets and radio waves instead of X-rays, making it particularly useful for examining muscles, tendons, and ligaments where extraosseous Ewing’s sarcoma often develops. Doctors rely on MRI to see how deeply the tumor has grown into surrounding tissues and whether it is affecting nearby blood vessels or nerves.^[1]

To check if the cancer has spread to bones, doctors may order a bone scan. This test involves injecting a small amount of radioactive material into a vein, which travels through the bloodstream and accumulates in areas of abnormal bone activity. A special camera then takes pictures that can reveal metastases in the skeleton.^[3]

Positron emission tomography, or PET scans, are another imaging tool that can help detect cancer cells throughout the body. During a PET scan, a small amount of radioactive sugar is injected into the body. Cancer cells, which use more energy than normal cells, absorb more of this sugar and show up as bright spots on the scan. PET scans are particularly useful for identifying metastatic disease.^[3]

Tissue Examination

While imaging tests can suggest the presence of a tumor, the only way to confirm a diagnosis of extraosseous Ewing’s sarcoma is to examine the tumor tissue itself. This requires a biopsy, a procedure in which a doctor removes a small sample of tissue from the tumor so it can be studied under a microscope.^[1]

There are different types of biopsies, and the choice depends on the tumor’s location and size. A needle biopsy involves inserting a thin needle into the tumor to extract cells or tissue. An open biopsy, which is more invasive, involves making a small surgical cut to remove a larger piece of tissue. The tissue sample is then sent to a laboratory where a specialist called a pathologist examines it.

Under the microscope, extraosseous Ewing’s sarcoma appears as clusters of small, round, blue-staining cells. This characteristic appearance helps distinguish it from other types of cancer. However, microscopic examination alone is not always enough, because several other cancers can look similar under the microscope.^[1]

Immunohistochemical and Genetic Testing

To make a definitive diagnosis, doctors use additional laboratory techniques. Immunohistochemistry is a method that uses special antibodies to detect specific proteins on the surface of cancer cells. Extraosseous Ewing’s sarcoma cells often produce certain proteins that can be identified through this technique, helping to confirm the diagnosis.^[1]

Even more specific is genetic testing, which looks for particular changes in the tumor’s DNA. Most cases of Ewing’s sarcoma, including the extraosseous form, are caused by an abnormal fusion of genetic material. The most common genetic change involves a swap of material between chromosome 11 and chromosome 22, creating what is called a chromosomal translocation. This results in the fusion of the EWSR1 gene with the FLI1 gene, forming a new, abnormal gene called EWSR1-FLI1.^[3]

Testing for this genetic abnormality is extremely helpful because it is found in the vast majority of Ewing’s sarcoma cases and is not seen in most other cancers. If the EWSR1-FLI1 fusion gene is detected in the tumor sample, it provides strong evidence that the diagnosis is correct. In some cases, EWSR1 may fuse with other genes instead of FLI1, but the principle remains the same: the presence of this genetic change helps doctors distinguish Ewing’s sarcoma from other cancers that may look similar under the microscope.^[4]

Genetic and molecular testing has become an essential part of diagnosing extraosseous Ewing’s sarcoma. These tests not only confirm the diagnosis but also help doctors classify the tumor more accurately. Several genetic biomarkers have been established for this purpose, although researchers continue to study them to better understand their role and improve their use in clinical practice.^[1]

Physical Examination

Before ordering any tests, doctors usually perform a thorough physical examination. During this exam, the doctor will feel for any lumps or bumps on the body and ask detailed questions about the patient’s symptoms, including when the pain or swelling started, whether it has changed over time, and if anything makes it better or worse. The physical exam helps guide which imaging and laboratory tests are needed next.^[3]

Diagnostics for Clinical Trial Qualification

When patients with metastatic extraosseous Ewing’s sarcoma are considered for enrollment in a clinical trial, they often need to undergo additional or more detailed diagnostic tests. Clinical trials are research studies that test new treatments or combinations of treatments to see if they are safe and effective. Because these studies require precise information about each patient’s condition, the diagnostic standards are usually stricter than those used in routine clinical care.

One of the key requirements for clinical trial enrollment is confirmation of the diagnosis through both tissue examination and genetic testing. Trials may require that the presence of the EWSR1 gene fusion be documented before a patient can participate. This ensures that all patients in the study truly have Ewing’s sarcoma and not a different type of cancer that looks similar.^[4]

Imaging tests are also critical for clinical trial qualification. Trials often require recent scans—such as CT, MRI, PET, or bone scans—to document the size and location of all tumors, both the primary tumor and any metastases. These baseline images are essential because researchers need to compare them with scans taken later during treatment to see if the tumors are shrinking, staying the same, or growing. Imaging results help determine whether a treatment is working.^[1]

Blood tests are another standard part of the evaluation for clinical trial participation. Doctors check blood counts to ensure that the patient has enough healthy blood cells to tolerate treatment. They also test kidney and liver function, because many cancer treatments are processed by these organs. If the kidneys or liver are not working well, certain drugs could cause serious harm.^[3]

In addition to these standard tests, some clinical trials may require more specialized testing. For example, a trial studying a new drug that targets a specific protein may require that the patient’s tumor be tested to see if it produces that protein. If the tumor does not have the target, the patient would not benefit from the drug and would not be eligible for that particular trial.

Another important aspect of clinical trial diagnostics is the assessment of the patient’s overall health and ability to tolerate treatment. Doctors use a system called performance status to evaluate how well a patient can carry out daily activities. A patient with good performance status can walk, eat, and care for themselves with little difficulty, while someone with poor performance status may be bedridden or need significant help. Clinical trials often have specific performance status requirements because treatments can be demanding, and patients need to be strong enough to participate safely.

The goal of all these diagnostic steps—whether for routine care or for clinical trial qualification—is to gather as much accurate information as possible about the cancer. This information helps doctors make the best treatment decisions and gives patients the clearest picture of what to expect as they move forward in their care.